Jazz Pharmaceuticals plc Earnings Recaps
Q3 2025
Nov 7, 2025
Jazz Pharmaceuticals achieved record revenues of over $1.1 billion in Q3 2025, fueled by strong sales across its product portfolio and two significant FDA approvals, paving the way for continued growth and strategic advancements.
Key takeaways
- Secured FDA approvals for Modeyso and Zepzelca, expanding treatment options for severe conditions.
- Strong commercial performance driven by Xywav's 11% year-over-year growth, contributing $431 million in net sales.
- Narrowed 2025 revenue guidance to $4.175 billion - $4.275 billion, reflecting confidence in future performance.
- Completed settlements in Xyrem antitrust litigation, allowing focus on strategic execution and shareholder value.
- Strengthened the pipeline with the Saniona licensing agreement for a promising epilepsy candidate, SAN2355.